 |
|
|
| |
Long-Term Follow-Up After a Switch to Bictegravir,
Emtricitabine, Tenofovir Alafenamide (B/F/TAF) from a
Boosted Protease Inhibitor-Based Regimen
|
| |
| |
Glasgow 2020, October 5-8 virtual
Reported by Jules Levin
Jurgen K. Rockstroh,1 Jean-Michel Molina,2 Frank Post,3 Julie Fox, 4 Ellen Koenig,5 Eric S. Daar, 6 Edwin DeJesus, 7 Peter Ruane, 8 Gordon Crofoot, 9 Godson Oguchi,10 Catherine Creticos,11 Angela SY Liu,12 Kristen Andreatta,12 Hiba Graham,12 Diana M. Brainard,12 Hal Martin12
1Bonn University Hospital, Venusburg, Germany; 2Saint-Louis Hospital, Paris, France; 3King's College Hospital NHS Foundation Trust, Kings College London, UK; 4Guy's and St. Thomas' NHS Foundation Trust; 5Inst. Domin Estudio
Virologicos, Santo Domingo, Dominican Republic; 6Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA; 7Orlando Immunology Center, Orlando, FL, USA; 8Ruane Clinical Research Group, Inc., Los Angeles, CA, USA; 9The
Crofoot Research Center, Houston, TX, USA; 10Midland Florida Clinical Research Center, LLC, Deland, FL, USA; 11Howard Brown Health Center, Chicago, IL, USA; 12Gilead Sciences, Foster City, CA, USA
|
| |
|
|
|
|
|
